Cancer Drug stories:
UPDATE 1-Poniard cancer drug misses study goal; shares plunge
Nov 16th, 2009 - Reuters
* Says late-stage study data misses primary endpoint * Shares down more than 80 pct Nov 16 (Reuters) - Poniard Pharmaceuticals Inc (PARD.O)said a late-stage study of its experimental lung cancer drugmissed the main goal...
Local biotech firm wins OK on cancer drug
Nov 6th, 2009 - Boston
Gloucester Pharmaceuticals, a six-year-old Cambridge biotechnology start-up, has won approval from the Food and Drug Administration to market its first drug in the United States. The drug...
Sanofi Sees Profit Gain From Swine Flu as Generics Erode Sales
Oct 30th, 2009 - Bloomberg
Oct. 30 (Bloomberg) -- Sanofi-Aventis SA raised its full-year profit growth forecast, saying demand for swine fluvaccines has buoyed sales this quarter. Earnings per share...
SciClone to restructure, cut work force 17 percent
Oct 28th, 2009 - Boston
FOSTER CITY, Calif.—SciClone Pharmaceuticals Inc. on Wednesday said it will cut 17 percent of its work force -- which was at 227 people at the end of 2008 -- as part of a corporate restructuring.
Celgene's 3rd-quarter profit jumps 58 percent on cancer drug sales, tops forecasts
Oct 22nd, 2009 - ChicagoTribune
SUMMIT, N.J. (AP) - Biotech drugmaker Celgene Corp. said Thursday its third-quarter profit surged 58 percent on a boost in sales of the cancer drugs Revlimid and Vidaza. The company earned $216.8 million...



